What is Cotellic (cobimetinib) for?
Cobimetinib is a cancer medicine used to treat adults with melanoma. Cotellic (cobimetinib) is indicated in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The presence of BRAF V600E or V600K mutation in tumour samples needs to be confirmed prior to initiation of treatment1,2,3.
How does Cotellic (cobimetinib) work?
The active substance in Cotellic, cobimetinib, is a kinase inhibitor. In melanoma with the BRAF V600 mutation, an abnormal form of the protein BRAF is produced, which switches on a protein (MEK), involved in stimulating normal cell division. This encourages the cancer to develop by allowing uncontrolled division of the cancer cells.
By blocking this protein cobimetinib slows down the growth and spread of the cancer. Cobimetinib is only given to patients whose melanoma is caused by the BRAF V600 mutation and must be used in combination with the BRAF inhibitor vemurafenib1. Vemurafenib is an anticancer medicine that has been widely approved (e.g. by FDA since 20115, EMA since 20126, and TGA since 20127.
Is Cotellic (cobimetinib) approved?
Cobimetinib was approved by:
FDA (USA) on November 10, 20158
EMA (EU) on November 20, 20151
TGA (AUS) on April 5, 20163
How is Cotellic (cobimetinib) taken?
60 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity
Confirm the presence of BRAF V600E or V600K mutation in tumour sample prior to initiation of treatment
Complete information about cobimetinib dosage and administration can be found in the resources section.
Note: Consult your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Cotellic (cobimetinib)?
Common adverse reactions
The most common adverse reactions (≥20% of patients) listed in the prescribing information include:
- photosensitivity reaction
Serious adverse reactions
The serious adverse reactions (≥5% of patients) listed in the prescribing information include:
- grade 3 or 4 abnormal blood counts
- increased GGT
- increased CPK
- increased ALT
- increased AST
- increased alkaline phosphatase
Use in a specific population
Cotellic (cobimetinib) can be fatal for a fetus, it is advised to avoid pregnancies and breastfeeding.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information2,3,4.